Huajin Pharmaceuticals Selected in 2022 Guangzhou "Future Unicorn" Innovative Enterprises List

Recently, the list of "Unicorn" innovative enterprises in Guangzhou in 2022 was officially released. Huajin Pharmaceutical stood out with its excellent drug research and development capabilities and excellent results and was successfully selected into the list of "Unicorn" innovative enterprises in Guangzhou in 2022.

Huajin Medicine is the world's first (first-in-class) development enterprise of bacterial vector genetic engineering biological products targeting the regulation of tumor amino acid metabolism. The core product oncolytic bacterium SGN1 (Samwick®,SalMet-Vec®) is carrying out Phase I/IIa registered clinical trials of intravenous and intratumoral administration for broad-spectrum solid tumors in the United States and Taiwan, China. The award of "future unicorn" innovative enterprise is an affirmation of Huajin Pharmaceutical's development stage and enterprise value, and will also encourage the company to continue to move towards the goal of a real unicorn enterprise.

Guangzhou "Unicorn" Innovative Enterprise List

Guangzhou "Unicorn" innovative enterprises list is an authoritative list under the guidance of Guangzhou Science and Technology Bureau and sponsored by Guangzhou Science and Technology Innovation Enterprise Association. After enterprise application, expert evaluation and other procedures, the selection aims to tap innovative enterprises with strong innovation, fast growth and great development potential in Guangzhou, cultivate leading innovative enterprises in the future, and give full play to the leading and exemplary role of enterprise innovation. it is an important weather vane for the development of Guangzhou's new economy.Among them, the "Future Unicorn" list of innovative companies is positioned to explore innovative companies with the potential to become "unicorns", for companies that have received institutional equity investment and a market valuation of between 0.1 billion and 1 billion US dollars.